|
Age related macular degeneration
|
0.370 |
Biomarker
|
disease |
BEFREE |
Mutation in a short-chain collagen gene, CTRP5, results in extracellular deposit formation in late-onset retinal degeneration: a genetic model for age-related macular degeneration.
|
12944416 |
2003 |
|
Age related macular degeneration
|
0.370 |
GeneticVariation
|
disease |
BEFREE |
The macular degeneration-linked C1QTNF5 (S163) mutation causes higher-order structural rearrangements.
|
24531000 |
2014 |
|
Age related macular degeneration
|
0.370 |
GeneticVariation
|
disease |
BEFREE |
All individuals with either LAZ and/or macular degeneration carry the same CTRP5 S163R mutation, which is transmitted in autosomal dominant manner.
|
16123441 |
2005 |
|
Age related macular degeneration
|
0.370 |
Biomarker
|
disease |
BEFREE |
Crystal structure of the globular domain of C1QTNF5: Implications for late-onset retinal macular degeneration.
|
22892318 |
2012 |
|
Retinitis Pigmentosa
|
0.300 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
|
Adult-onset night blindness
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Rod-Cone Dystrophy
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Obesity
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
Overweight/obese individuals (BMI ≥ 25 kg/m<sup>2</sup>) showed a lower serum CTRP5 level than lean subjects (BMI < 25 kg/m<sup>2</sup>) in the study population (124.1 (99.12-147.37) vs. 103.9 (79.15-124.25) <i>μ</i>g/L; <i>P</i> < 0.01).
|
30595692 |
2018 |
|
Obesity
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
We hypothesized that adipocyte C1QTNF5 expression in subcutaneous (sc) adipose tissue (AT) would correlate with the degree of obesity, systemic CTRP5 serum levels, and early AT and metabolic dysfunction in children.
|
28239164 |
2017 |
|
Obesity
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
Adipose expression of CTRP5 was markedly upregulated in obese and diabetic humans and in genetic and dietary models of obesity in rodents.
|
27143553 |
2016 |
|
Obesity
|
0.060 |
Biomarker
|
disease |
BEFREE |
Our findings indicated that CTRP5 is a novel promising therapeutic target for obesity and other metabolic diseases.
|
30717975 |
2019 |
|
Obesity
|
0.060 |
Biomarker
|
disease |
BEFREE |
As a member of the tumor necrosis factor-α-related protein family, complement-1q tumor necrosis factor-α-related protein isoform 5 (CTRP5) has been found to be associated with obesity and insulin resistance (IR).
|
31070007 |
2020 |
|
Obesity
|
0.060 |
Biomarker
|
disease |
BEFREE |
Circulating Serum Myonectin Levels in Obesity and Type 2 Diabetes Mellitus.
|
31340393 |
2019 |
|
Macular degeneration
|
0.050 |
Biomarker
|
disease |
BEFREE |
Crystal structure of the globular domain of C1QTNF5: Implications for late-onset retinal macular degeneration.
|
22892318 |
2012 |
|
Macular degeneration
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
Characterisation of a C1qtnf5 Ser163Arg knock-in mouse model of late-onset retinal macular degeneration.
|
22110650 |
2011 |
|
Macular degeneration
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
Disease mechanisms in late-onset retinal macular degeneration associated with mutation in C1QTNF5.
|
16600989 |
2006 |
|
Macular degeneration
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
All individuals with either LAZ and/or macular degeneration carry the same CTRP5 S163R mutation, which is transmitted in autosomal dominant manner.
|
16123441 |
2005 |
|
Macular degeneration
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
The macular degeneration-linked C1QTNF5 (S163) mutation causes higher-order structural rearrangements.
|
24531000 |
2014 |
|
Diabetes
|
0.030 |
Biomarker
|
disease |
BEFREE |
We assessed whether plasma concentrations of three known myokines [myonectin, myostatin, and fibroblast-derived growth factor 21 (FGF-21)] would be associated with direct and indirect indicators of insulin resistance (IR) in individuals who did not have a diagnosis of diabetes.
|
29445355 |
2018 |
|
Diabetes
|
0.030 |
Biomarker
|
disease |
BEFREE |
CTRP5 is likely a marker for type 2 diabetes in humans.
|
31070007 |
2020 |
|
Diabetes
|
0.030 |
Biomarker
|
disease |
BEFREE |
Inhibition of CTRP5 action may result in the alleviation of insulin resistance associated with obesity and diabetes.
|
27143553 |
2016 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Serum CTRP3 and CTRP5 levels were markedly decreased in patients with T2DM compared to controls (p<0.05) and inversely associated with T2DM.
|
28632765 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Moreover, serum myonectin levels were correlated with metabolic markers of T2DM.
|
31340393 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.030 |
Biomarker
|
disease |
BEFREE |
nT2DM and IGT subjects had higher circulating myonectin concentrations than normal subjects (82.3 ± 47.6 and 68.9 ± 46.6 vs. 45.2 ± 23.5 µg/L, P < 0.05 or P < 0.01).
|
29161407 |
2018 |
|
Metabolic Syndrome X
|
0.030 |
Biomarker
|
disease |
BEFREE |
CTRP-5 was detected in adipose tissue of mice and plays a role in the context of the metabolic syndrome.
|
23430573 |
2013 |